Original Article
A Controlled Study of Adenoviral-Vector–Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis
N Engl J Med 1995; 333:823-831September 28, 1995
- Abstract
Background
Cystic fibrosis is a monogenic disease that deranges multiple systems of ion transport in the airways, culminating in chronic infection and destruction of the lung. The introduction of a normal copy of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the airway epithelium through gene transfer is an attractive approach to correcting the underlying defects in patients with cystic fibrosis. We tested the feasibility of gene therapy using adenoviral vectors in the nasal epithelium of such patients.
Methods
An adenoviral vector containing the normal CFTR complementary DNA in four logarithmically increasing doses (estimated multiplicity of infection, 1, 10, 100, and 1000), or vehicle alone, was administered in a randomized, blinded fashion to the nasal epithelium of 12 patients with cystic fibrosis. Gene transfer was quantitated by molecular techniques that detected the expression of CFTR messenger RNA and by functional measurements of transepithelial potential differences (PDs) to assess abnormalities of ion transport specific to cystic fibrosis. The safety of this treatment was monitored by nasal lavage and biopsy to assess inflammation and vector replication.
Results
The adenoviral vector was detected in nasal-lavage fluid by culture, the polymerase chain reaction (PCR), or both in a dose-dependent fashion for up to eight days after vector administration. There was molecular evidence of gene transfer by reverse-transcriptase PCR assays or in situ hybridization in five of six patients treated at the two highest doses. However, the percentage of epithelial cells transfected by the vector was very low (<1 percent), and measurement of PD across the epithelium revealed no significant restoration of chloride transport or normalization of sodium transport. At the lower doses of vector, there were no toxic effects. However, at the highest dose there was mucosal inflammation in two of three patients.
Conclusions
In patients with cystic fibrosis, adenoviral-vector–mediated transfer of the CFTR gene did not correct functional defects in nasal epithelium, and local inflammatory responses limited the dose of adenovirus that could be administered to overcome the inefficiency of gene transfer.
Media in This Article
Figure 1
Reverse-Transcriptase PCR Assays for Adenoviral-Vector–Mediated Expression of CFTR mRNA in the Nasal Epithelium of Patients with Cystic Fibrosis.Figure 3
Assay of Nasal PD to Determine the Extent of CFTR-Mediated Chloride Transport before and after the Administration of Adenoviral Vector or Vehicle in Each Cohort.Article Activity
- Article
Cystic fibrosis is a recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.1-4 The normal CFTR gene codes for a protein (CFTR) that plays a key part in epithelial transport of salt and water.5,6 Mutations in CFTR result in abnormal secretions that obstruct and ultimately damage epithelium in many areas of the body.7
The principal cause of death among patients with cystic fibrosis is lung disease. Patients who are homozygous for mutations in the CFTR gene have defective cyclic AMP (cAMP)–regulated secretion of chloride8,9 and elevated absorption of sodium10 in the airway epithelium, which thicken airway secretions, impair mucociliary clearance, and produce chronic bacterial infection of the airways.5-7,11 Carriers of a mutation in the CFTR gene do not have lung disease, which indicates that a single copy of the normal CFTR gene is sufficient for normal defense of the lung. The transfer of a single copy of normal CFTR into all epithelial cells affected by cystic fibrosis might be expected to correct airway function.
We performed a double-blind, vehicle-controlled study to assess the efficacy and safety of gene transfer to treat disease of the airways associated with cystic fibrosis. An adenoviral vector was selected for this study because of its reportedly high efficiency in gene transfer in both animal models12 and preclinical studies of human airway epithelium in vitro.13 The study used a dose-escalation protocol, in which the dose was defined with reference to previous studies14,15 by the estimated multiplicity of infection (the number of infectious adenoviral vectors delivered per airway epithelial cell). We confined our treatment to the nasal epithelium, which has morphologic features16 and cystic fibrosis–specific defects of ion transport similar to those of the lower airways,17 because of concern about safety generated in preclinical studies in which lung tissue was treated with adenoviral vector,18-20 and also because efficacy can be tested accurately and repeatedly at this site.
Methods
This protocol was approved by the Committee for Protection of the Rights of Human Subjects, the Recombinant Advisory Committee of the National Institutes of Health, and the Food and Drug Administration.21 Additional information about the methods used is available from the National Auxiliary Publications Service (NAPS).
Study Subjects
Twelve patients with stable pulmonary disease (mean [±SE] forced expiratory volume in one second, 65.0±6.9 percent of the predicted value) and pancreatic exocrine insufficiency were studied (Table 1Table 1
Study Design and Dosage of Adenoviral Vector.). All were seropositive for adenovirus.22 The women had negative pregnancy tests and used contraceptive methods. Informed consent was obtained from all patients.21 Gene-Transfer Vector
We used a replication-defective adenovirus serotype 5 vector with a strong enhancer (cytomegalovirus)–promoter (chicken β-actin [CB]) (Ad5-CB-CFTR, recently designated H5.020CBCFTR)21 to express the CFTR complementary DNA (cDNA). Three lots of the adenoviral vector with particle:plaque-forming unit ratios ranging from 20:1 to 50:1 were produced by Good Manufacturing Practices at the Institute for Human Gene Therapy (University of Pennsylvania) and shipped frozen (-70°C) to the University of North Carolina at Chapel Hill. Each lot was efficacious for CFTR transduction by the Western blot assay and for chloride secretion in vitro, and vector was titered and shown to be efficacious (by the Western blot assay) after dilution with 2 ml of 3 percent glycerol in phosphate-buffered saline (vehicle).
Study Design
Dosage
The adenoviral vector was administered to four cohorts of three patients each, in logarithmically increasing doses. The dose of a biologic vector is complex and may be described in terms of the concentration (in plaque-forming units per milliliter), the total dose (in plaque-forming units), and the estimated number of vectors administered per epithelial cell (the estimated multiplicity of infection) (Table 1). Two milliliters of vehicle or adenoviral vector was infused (for 30 minutes) under direct vision onto the inferior and medial surfaces of the inferior turbinate and the nasal floor (approximately 8 cm2, or 2×107 surface epithelial cells23) of the right nostril, with the subject in a right lateral recumbent position. After treatment, the subject remained in that position for an additional 20 minutes. The subject was then repositioned in the left lateral recumbent position, and the left nostril was treated with the alternative solution. Dosing-simulation studies indicated that 58±4 percent of the instilled solution remained in the nose for 50 minutes. The identity of the instilled solutions was known to only one investigator.
Detection of Vector
We monitored for residual adenoviral vector in urine samples and samples obtained with a swab from the nose, pharynx, and rectum by viral culture of 293 cells21 and by a nested polymerase chain reaction (PCR) using primers that amplify the L3 region of the adenovirus and sequences of CFTR specific to the vector.
Safety
We monitored symptoms, vital signs, and blood counts and inspected the nose visually each day. Chest radiography, blood-chemistry testing, and spirometry were performed at the beginning and end of the study. Serum titers of adenoviral antibody were measured before and 21 days after treatment.22 Nasal-lavage fluid was analyzed daily for total cell counts (by hemocytometry), differential cell counts (in cytospin preparations), and the presence of cytokines (interleukin-1β, interleukin-6, interleukin-8, and interleukin-10) and albumin.24,25 Six days after treatment, biopsy specimens from the inferior turbinates were obtained, snap-frozen (in liquid nitrogen), and analyzed for inflammatory cell infiltrates.26
Efficacy of Gene Transfer
A reverse-transcriptase PCR assay of DNase-treated RNA from scrape-biopsy specimens of nasal epithelium obtained 6 and 21 days after dosing was performed27; vector-specific CFTR messenger RNA (mRNA) was amplified with primers across the junction of 3' CFTR and untranslated viral sequences. In situ hybridization was performed with riboprobes specific for expressed vector sequences.28
The functional efficacy of the vector treatment was assayed by measuring the potential difference (PD), or voltage, across the nasal epithelium on 3 separate days before treatment, then daily for up to 14 days, and on day 21 after treatment.16,17,29 The protocol measured the basal PD (an index of sodium transport and mucosal integrity) and indexes of sodium transport (the basal PD and the degree of inhibition by a sodium-channel blocker, amiloride [10-4 M]); basal chloride permeability (the response to perfusion with a chloride-free solution containing amiloride); cAMP-regulated (CFTR) secretion of chloride (the response to isoproterenol [10-5 M] in the perfusate in the presence of a chloride-free solution); and the capacity of the epithelium to secrete chloride (the effect of ATP [10-4 M] in the chloride-free perfusate on calcium-mediated chloride secretion29). PD was measured under the inferior turbinate (normal epithelium), the nasal floor, and the medial surface (metaplastic epithelium) of the inferior turbinate.16
Statistical Analysis
The primary analysis of the effects of treatment on nasal PD used a mixed model to fit repeated measures of the values obtained from days 1 through 6 after treatment with vehicle or adenoviral vector (the post-treatment values), using the base-line values (those obtained from day 5 before treatment to the day of treatment) as predictive variables in each cohort.30 The secondary analysis compared the mean base-line and post-treatment values by paired t-tests in each cohort. Each analysis yielded the same outcome. Mean base-line and post-treatment concentrations of inflammatory cells and mediators in nasal-lavage fluid were compared by paired t-tests. Scores for inflammatory-cell infiltrates in the biopsy specimens treated with vehicle were compared with those in the specimens treated with adenoviral vector by paired t-tests. P values of less than 0.05 were considered to indicate statistical significance.
Results
Detection of Vector
Culture
Vector was routinely cultured from samples obtained 20 minutes after dosing from nostrils dosed with adenoviral vector, and for up to four days after higher doses (estimated multiplicity of infection, >100). One patient (Patient 11; estimated multiplicity of infection, 1000) had positive cultures from the vehicle-dosed nostril on day 1 and from rectal samples obtained one and two days after dosing. Additional data on individual patients are available from NAPS.
PCR
Adenoviral-vector DNA was detected by PCR in samples obtained from the dosed nostrils for two to eight days after the administration of higher doses (estimated multiplicity of infection, >100). Vector DNA was detected in the vehicle-dosed nostrils of two patients (Patients 4 and 10) one and four days, respectively, after dosing, and from the pharynx of two patients (Patients 8 and 10) two days after dosing. In urine samples, two patients (Patients 2 and 8) had PCR products compatible with shedding of wild-type adenoviral DNA (L3/E1a-positive, CFTR-negative).31,32 One patient (Patient 4) was positive by PCR for L3 but not for E1a or CFTR on day 1 after treatment, making it impossible to distinguish between wild-type adenoviral DNA and the degraded vector.
Molecular Assessment of Efficacy
Reverse-Transcriptase PCR Assay
Figure 1Figure 1
Reverse-Transcriptase PCR Assays for Adenoviral-Vector–Mediated Expression of CFTR mRNA in the Nasal Epithelium of Patients with Cystic Fibrosis. shows the PCR product (210 base pairs [bp]) of vector-expressed CFTR mRNA from inferior-turbinate epithelium obtained six days after the administration of adenoviral vector; vector-specific products were observed in several samples containing reverse transcriptase. The summary data (Table 2Table 2
Presence or Absence of Adenoviral-Vector CFTR mRNA in Samples of Nasal Epithelium Obtained Six Days after Treatment.) show that only subjects who received the higher doses expressed vector-specific mRNA. No subject had a positive reverse-transcriptase PCR product from samples obtained three weeks after treatment. Samples from the side of the nose on which vehicle was administered were negative.In Situ Hybridization
Biopsy specimens from the six subjects given the higher doses (cohorts 3 and 4; estimated multiplicity of infection, >100) were studied. Previous studies and the positive controls used in this study (CFPAC cells) indicated that in situ signals could be detected in single cells probed for CFTR mRNA expressed in response to the strong CB promoter.33 Approximately 14,000 cells were examined in two sections from a biopsy specimen. No in situ signal was detected in specimens from five of six subjects. In one patient who received the highest dose (Patient 11), four patchy areas (i.e., containing approximately 15 to 20 cells) of gene transfer were detected; two were in regions of intact airway epithelium, and two were in areas of damage, including expression in the submucosa. No signal was detected in the nostrils treated with vector when the samples were treated with RNase or studied with sense probes, nor was an antisense signal detected in the nostrils treated with vehicle.
Assessment of Biologic Efficacy by Measurements of PD
The measurements of PD under the inferior surface of the turbinate (in normal ciliated epithelium) are summarized below.
Basal PD
A total of 1440 PD measurements were made (Figure 2Figure 2
Basal Transepithelial Potential Difference (PD) before and after the Administration of Adenoviral Vector or Vehicle in Each Cohort.). There was no change in basal PD among patients who were exposed to vector at an estimated multiplicity of infection of 1, 10, or 100 (cohorts 1, 2, and 3). In contrast, the mean basal PD decreased by 15.1±1.6 mV after the administration of vector at the highest dose (cohort 4, including Patients 10, 11, and 12; estimated multiplicity of infection, 1000). There was no significant change in the PD of epithelium treated with vehicle in any cohort.Inhibition by Amiloride
There was no change in the percentage of inhibition of the basal PD with amiloride, a sodium-channel blocker, after treatment with either vector or vehicle in any cohort (inhibition in cohort 4, 69.5±2.7 percent before treatment with vector and 68.5±2.1 percent afterward; estimated multiplicity of infection, 1000).
Basal Chloride Permeability
There were no systematic changes in PD after chloride substitution, even in the highest-dose cohort (change in PD in nostrils treated with vector in cohort 4, 5.8±0.7 mV before treatment and 4.5±0.4 mV afterward; in nostrils treated with vehicle, 4.7±0.6 and 4.5±0.5 mV, respectively).
Isoproterenol-Regulated Chloride Secretion
We found no evidence of isoproterenol (cAMP)-induced increases in PD (chloride secretion), even in the highest-dose cohort (change in nostrils treated with vector in cohort 4, 0.2±0.3 mV before treatment and -0.2±0.6 mV afterward; in nostrils treated with vehicle, 0.8±0.4 and 0.3±0.3 mV, respectively).
Combined Response to Chloride Substitution and Isoproterenol
The change in nasal PD in amiloride-treated epithelium in response to both chloride substitution and treatment with isoproterenol best discriminates patients with cystic fibrosis from normal subjects29,34 (Figure 3Figure 3
Assay of Nasal PD to Determine the Extent of CFTR-Mediated Chloride Transport before and after the Administration of Adenoviral Vector or Vehicle in Each Cohort.). The individual data points, relative to previously published values from normal subjects29 (shaded area in Figure 3), are shown for each cohort. There were no significant changes in PD, even in the highest-dose cohort (change in PD with vector in cohort 4, 4.9±0.3 mV before treatment and 2.0±1.7 mV afterward; with vehicle, 4.6±1.6 and 3.8±1.4 mV, respectively).ATP-Regulated Chloride Secretion
Large ATP-induced increases in PD, reflecting calcium-mediated chloride secretion, were detected in all cohorts before treatment (change in PD with vehicle, -19.9±2.7 mV; with vector, -20.6±2.4 mV), and they persisted after treatment (-20.8±2.3 and -18.7±2.4 mV, respectively).
Data similar to those given above for normal epithelium were obtained in each cohort for measurements of PD on the medial surface of the inferior turbinate (metaplastic epithelium).
Safety
No patient had significant changes in vital signs, complete blood count, blood chemistry, chest radiographs, or results of spirometric analysis. No patient receiving doses of adenoviral vector with an estimated multiplicity of infection of 1, 10, or 100 (cohorts 1, 2, and 3) had local symptoms or signs. Two patients (Patients 10 and 12) in cohort 4 (the highest-dose group) had symptoms and signs of toxic effects within 12 to 24 hours of the administration of the dose. One patient (Patient 10) had an earache and an inflamed tympanic membrane; the other (Patient 12) had jaw pain and mandibular-angle (nodal) tenderness; these symptoms were all ipsilateral to the site of administration of vector. Visual inspection by an ear, nose, and throat specialist who was unaware of the dosing schedule and the symptoms of the patients revealed unilateral induration of the nasal mucosa and increases in mucosal sensitivity and secretions that were confined to the nostril treated with vector. Maximal symptoms and signs occurred after 48 to 96 hours, and there was complete resolution within three weeks. Further information on individual patients is available from NAPS.
Nasal Lavage and Measurements of Cells and Cytokines
No difference in the total cell count or in the quantity of interleukin-1β, interleukin-6, interleukin-8, and interleukin-10 in nasal-lavage fluid was noted on days 1 through 6 after the administration of vector or vehicle in any cohort. The nostrils treated with vector in the highest-dose cohort had a greater increase in the total number of cells, neutrophils, interleukin-6, and interleukin-8 in response to the nasal biopsy than did the nostrils treated with vehicle, suggesting that the adenoviral vector primed the epithelium for an inflammatory response.
Albumin in Nasal-Lavage Fluid
There was no change in the albumin concentration in nasal-lavage fluid in Patients 1 through 9 (cohorts 1, 2, and 3) after the administration of either vector or vehicle on days 1 through 6, as compared with the base-line values (Figure 4Figure 4
Mean (±SE) Change from Base Line in the Albumin Content of Nasal-Lavage Fluid during the Six Days after the Administration of Vehicle (Open Bars) or Vector (Solid Bars), Expressed as the Percentage of Change from the Values before Treatment.). In contrast, in the highest-dose cohort (cohort 4), the albumin concentration doubled in the nostrils treated with vector, but not in those treated with vehicle. This increase was approximately threefold in the two symptomatic patients (Patients 10 and 12).Histopathological Analysis of Nasal-Biopsy Specimens
There was no difference in the number of inflammatory cells in the epithelium or submucosa between the biopsy specimens from the nostrils treated with adenoviral vector and those treated with vehicle in any cohort.
Serum Antibodies to Adenovirus
One patient (Patient 10) in the highest-dose cohort had an increase (from 1:80 to 1:1280) in the titer of neutralizing antibody 21 days after the administration of the vector.
Discussion
In this double-blinded, vehicle-controlled trial of adenoviral vector in patients with cystic fibrosis, we found molecular evidence of low-efficiency gene transfer and expression of the normal CFTR mRNA in nasal epithelium, but there was no significant functional correction of abnormalities in ion transport. The absence of adenoviral-vector tropism for surface columnar cells,35 which normally express CFTR,36 explains this failure. This problem cannot be overcome by simply increasing the dose of the vector, because the highest dose we used (with an estimated multiplicity of infection of 1000) was associated with inflammatory responses in two of three patients; in addition, studies in animals indicate a wide spectrum of toxic effects at higher doses.18-20
Careful attention was paid to the design, production, and administration of the vector we used. With its strong promoter, this vector was completely effective in correcting cystic fibrosis–associated defects of chloride35 and sodium transport in the airway epithelium in vitro.37 Three separate lots of vector were produced21,38 and tested for the titer and for the efficacy of CFTR gene transfer at two independent sites before their use. The adequacy of vector administration and the viability of the vector were confirmed by its detection in the nostril treated with vector up to eight days after the administration of the dose.
Two outcome variables were measured with respect to efficacy and were grouped on the basis of dosage. In the two lower-dose cohorts (cohorts 1 and 2; estimated multiplicity of infection, 1 and 10, respectively), we found little evidence of adenoviral-vector–mediated gene transfer. Only one of six patients was positive for gene transfer by the reverse-transcriptase PCR assay. This assay is sensitive to as few as 5 cells expressing vector CFTR mRNA among 500,000 cells not expressing this mRNA (0.001 percent); thus, the negative PCR data in these cohorts indicated that virtually no gene transfer occurred.39 The lack of functional correction of PD is consistent with this conclusion.
In the two higher-dose cohorts (cohorts 3 and 4; estimated multiplicity of infection, 100 and 1000, respectively), there was more evidence of gene transfer by the reverse-transcriptase PCR assay (four of six patients were positive). However, in situ hybridization, which is about one order of magnitude less sensitive than the PCR assay, detected expression in only one of these six patients, and the percentage of epithelial cells expressing CFTR mRNA in this one patient was low (less than 1 percent of the total number). Previous studies have shown that CFTR expression in 3 to 6 percent of the cells in the cystic fibrosis epithelium is required to correct the defect in chloride secretion.35,40 The PD protocols that are sensitive measures of CFTR-mediated chloride transport (e.g., the combined response to chloride substitution and isoproterenol) detected no systematic evidence of gene transfer, a finding consistent with an efficiency of gene transfer of less than 1 percent (Figure 3).
Three data points slightly above the range for cystic fibrosis in the highest-dose cohort could reflect patchy gene transfer or nonspecific effects of isoproterenol to activate a calcium-regulated chloride pathway in inflamed tissues. The relation between the efficiency of correction and the restoration of sodium transport is different from that for chloride, with virtually all cells requiring functional correction in order for the normalization of sodium transport to occur. There was no change in the percentage of inhibition of PD by amiloride in cohorts 3 and 4 to suggest a correction of sodium transport. Thus, in these cohorts vector-mediated gene transfer was detected, but its efficiency was too low for either the chloride or the sodium-transport defect associated with cystic fibrosis to be corrected.
No evidence of systemic toxic effects was noted in any patient, and no local toxic effects were noted in the cohorts receiving the three lowest doses. However, two of the three patients in the highest-dose cohort had symptoms and signs of local toxic effects in the mucosa, reduced basal PDs, and an increased flux of albumin into the fluid subsequently obtained by lavage from the nostrils treated with vector — observations consistent with epithelial damage.29,41,42 The syndrome was not associated with increased numbers of white cells or concentrations of cytokines in nasal-lavage fluid or with the cellular infiltrates associated with more chronic toxic effects (lasting 3 to 21 days) that have been identified in studies in animals.18-20 The rapid onset of the syndrome, like the severe pulmonary inflammatory reaction to Ad-CFTR, a similar adenoviral vector, in a patient described by Crystal et al.,15 coupled with recent studies in animals,43 suggests a neurogenic inflammatory cause.
Three observations were made that may pertain to the safety of the vector we used. First, there was dissemination of the vector — for example, to the pharynx and stool — at higher doses. Second, we detected vector DNA in the nasal cavity for up to eight days. The precise location of the vector in the epithelium is not known, and therefore the possibility of transmission or recombination of vector with wild-type adenovirus cannot be discounted.21,44 Finally, we observed an increase in the serum antibody titer in one patient receiving the highest dose of vector, which may have implications for the safety of the vector (e.g., enhanced immunologic responses on subsequent treatment with vector), implications for the efficacy of repeated administration of vector, or both.19
Two unblinded trials of Ad-CFTR in patients with cystic fibrosis have been reported. We could not confirm the correction of the cystic fibrosis–associated nasal defect of chloride transport reported by Zabner et al.14 Our study paralleled their study with respect to the site of deposition, and we used a vector with a stronger promoter and used that vector in higher concentrations (1.5 to 3 logs). The discrepancy probably relates to the PD protocols used to measure efficacy. The protocol used by Zabner et al. does not readily discriminate between patients with cystic fibrosis and normal subjects, making it difficult to interpret the results. The chloride-free PD protocols used in this study are highly sensitive in such discrimination29,34 and can detect full or even partial correction of chloride transport. This discrepancy highlights the need for standardized PD protocols and for complementary molecular and morphologic methods of assessing gene transfer.
Crystal et al.15 reported no quantitative nasal bioelectric data, but they did report positive results of immunocytochemical analysis for CFTR in one of four patients after bronchial brushing of a region that had received transbronchoscopic doses of vector. The evidence of transduction in bronchial cells may possibly reflect an increased efficiency of gene transfer in lower airway epithelium as compared with nasal epithelium, as has been reported in rodents.12,18 Alternatively, damage to airway epithelium can substantially enhance gene transfer by abrading the relevant target cells (i.e., the surface columnar cells) and exposing the vector to basal cells, which are more easily transduced but do not normally express CFTR.35 Thus, data pertaining to transduced epithelium from previously traumatized areas may not be representative of gene transfer to intact, undamaged epithelium, such as that treated in our study.
In summary, adenoviral-vector–mediated gene transfer to nasal epithelium affected by cystic fibrosis is inefficient. One potential strategy to overcome this problem would be to target adenoviral vectors to basal cells. Another would involve attempting to differentiate basal cells into columnar cells. A third would be to modify the vector itself so that it becomes tropic for columnar cells. If the nasal epithelium is typical of all human airway regions with respect to the observed inefficiency of adenoviral-vector–mediated gene transfer, it would appear prudent also to accelerate the development of alternative vectors,45 or to modify the adenoviral vectors, if gene transfer is to be successful in treating lungs in patients with cystic fibrosis.
Supported by grants from the Cystic Fibrosis Foundation (R026 and R881), the National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK47757), the National Heart, Lung, and Blood Institute (HL42384 and HL51818), and the National Institutes of Health (RR00046).
Dr. Wilson and Ms. Grossman hold equity in Genova, Inc., a company involved in the development of gene-transfer technology.
NAPS See NAPS document no. 05245 for seven pages of supplementary material. Order from NAPS c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163-3513.
We are indebted to K. Burns, C. Foy, J. Robinson, J. Winders, C.-H. Wong, and I. Wortman for expert technical assistance, to L. Dudus and H. Ye for assistance with the in situ hybridization studies, to P. Noone and W. Bennett for assistance with the dosing-simulation studies, to K. Kozarsky for assistance in the serologic testing for adenovirus by the Western blot assay, to L. Brown for editorial assistance, to the nursing staff of the General Clinical Research Center for expert patient care, and to the patients who participated in this challenging study.
Source Information
From the Department of Medicine, Cystic Fibrosis–Pulmonary Research and Treatment Center (M.R.K., K.W.H., Z.Z., J.C.O., K.R.J., L.G.J., R.C.B.), and the Departments of Pediatrics (T.L.N., P.-C.H., M.W.L.) and Biostatistics (L.J.E.), School of Public Health, University of North Carolina, Chapel Hill; and the Institute for Human Gene Therapy and the Department of Molecular and Cellular Engineering, University of Pennsylvania, Philadelphia (J.F.E., M.G., J.M.W.).
Address reprint requests to Dr. Knowles at the Cystic Fibrosis–Pulmonary Research and Treatment Center, 724 Burnett–Womack Bldg., CB 7020, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7020.
- References
References
1
Riordan JR ,Rommens JM ,Kerem B , et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1006-1073[Erratum, Science 1989;245:1437.]
CrossRef2
Rommens JM ,Iannuzzi MC ,Kerem B , et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065
CrossRef | Web of Science | Medline3
Kerem B ,Rommens JM ,Buchanan JA , et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080
CrossRef | Web of Science | Medline4
Collins FS . Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-779
CrossRef | Web of Science | Medline5
Boucher RC . Human airway ion transport. Am J Respir Crit Care Med 1994;150:581-593
Web of Science | Medline6
Quinton PM . Cystic fibrosis: a disease in electrolyte transport. FASEB J 1990;4:2709-2717
Web of Science | Medline7
Davis PB. Pathophysiology of the lung disease in cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. Vol. 64 of Lung biology in health and disease. New York: Marcel Dekker, 1993:193-218.
8
Widdicombe JH ,Welsh MJ ,Finkbeiner WE . Cystic fibrosis decreases the apical membrane chloride permeability of monolayers cultured from cells of tracheal epithelium. Proc Natl Acad Sci U S A 1985;82:6167-6171
CrossRef | Web of Science | Medline9
Stutts MJ ,Cotton CU ,Yankaskas JR , et al. Chloride uptake into cultured airway epithelial cells from cystic fibrosis patients and normal individuals. Proc Natl Acad Sci U S A 1985;82:6677-6681
CrossRef | Web of Science | Medline10
Boucher RC ,Stutts MJ ,Knowles MR ,Cantley L ,Gatzy JT . Na+ transport in cystic fibrosis respiratory epithelia: abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986;78:1245-1252
CrossRef | Web of Science | Medline11
Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 6th ed. Vol. 2. New York: McGraw-Hill, 1989:2649-80.
12
Rosenfeld MA ,Yoshimura K ,Trapnell BC , et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992;68:143-155
CrossRef | Web of Science | Medline13
Zabner J ,Couture LA ,Smith AE ,Welsh MJ . Correction of cAMP-stimulated fluid secretion in cystic fibrosis airway epithelia: efficiency of adenovirus-mediated gene transfer in vitro. Hum Gene Ther 1994;5:585-593
CrossRef | Web of Science | Medline14
Zabner J ,Couture LA ,Gregory RJ ,Graham SM ,Smith AE ,Welsh MJ . Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993;75:207-216
CrossRef | Web of Science | Medline15
Crystal RG ,McElvaney NG ,Rosenfeld MA , et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51
CrossRef | Web of Science | Medline16
Knowles MR ,Carson JL ,Collier AM ,Gatzy JT ,Boucher RC . Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981;124:484-490
Web of Science | Medline17
Knowles MR ,Gatzy J ,Boucher R . Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981;305:1489-1495
Full Text | Web of Science | Medline18
Yang Y ,Nunes FA ,Berencsi K ,Gonczol E ,Engelhardt JF ,Wilson JM . Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994;7:362-369
CrossRef | Web of Science | Medline19
Yei S ,Mittereder N ,Wert S ,Whitsett JA ,Wilmott RW ,Trapnell BC . In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 1994;5:731-744
CrossRef | Web of Science | Medline20
Simon RH ,Engelhardt JF ,Yang Y , et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther 1993;4:771-780
CrossRef | Web of Science | Medline21
Boucher RC ,Knowles MR ,Johnson LG , et al. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity: the University of North Carolina at Chapel Hill. Hum Gene Ther 1994;5:615-639
CrossRef | Web of Science | Medline22
Hierholzer JC. Adenoviruses. In: Schmidt NJ, Emmons RW, eds. Diagnostic procedures for viral, rickettsial and chlamydial infections. 6th ed. Washington, D.C.: American Public Health Association, 1989:219-64.
23
Mercer RR ,Russell ML ,Roggli VL ,Crapo JD . Cell number and distribution in human and rat airways. Am J Respir Cell Mol Biol 1994;10:613-624
Web of Science | Medline24
Noah TL ,Henderson FW ,Wortman IA , et al. Nasal cytokine production in viral acute respiratory infection of childhood. J Infect Dis 1995;171:584-592
CrossRef | Web of Science | Medline25
Peden DB ,Swiersz M ,Ohkubo K ,Hahn B ,Emery B ,Kaliner MA . Nasal secretion of the ozone scavenger uric acid. Am Rev Respir Dis 1993;148:455-461
Web of Science | Medline26
Curtis JL ,Byrd PK ,Warnock ML ,Beck JM ,Kaltreider HB . Pulmonary lymphocyte recruitment: depletion of CD8+ T cells does not impair the pulmonary immune response to intratracheal antigen. Am J Respir Cell Mol Biol 1993;9:90-98
Web of Science | Medline27
Highsmith WE ,Burch LH ,Zhou Z , et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994;331:974-980
Full Text | Web of Science | Medline28
Engelhardt JF ,Yankaskas JR ,Ernst SA , et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 1992;2:240-248
CrossRef | Web of Science | Medline29
Knowles MR ,Paradiso AM ,Boucher RC . In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-455
CrossRef | Web of Science | Medline30
Zeger SL ,Liang KY . An overview of methods for the analysis of longitudinal data. Stat Med 1992;11:1825-1839
CrossRef | Web of Science | Medline31
Stalder H ,Hierholzer JC ,Oxman MN . New human adenovirus (candidate adenovirus type 35) causing fatal disseminated infection in a renal transplant recipient. J Clin Microbiol 1977;6:257-265
Web of Science | Medline32
Mufson MA ,Belshe RB . A review of adenoviruses in the etiology of acute hemorrhagic cystitis. J Urol 1976;115:191-194
Web of Science | Medline33
Engelhardt JF ,Yankaskas JR ,Wilson JM . In vivo retroviral gene transfer into human bronchial epithelia of xenografts. J Clin Invest 1992;90:2598-2607
CrossRef | Web of Science | Medline34
Middleton PG ,Geddes DM ,Alton EWFW . Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994;7:2050-2056
CrossRef | Web of Science | Medline35
Grubb BR ,Pickles RJ ,Ye H , et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994;371:802-806
CrossRef | Web of Science | Medline36
Yankaskas JR ,Suchindran H ,Sarkadi B ,Nettesheim P ,Randell SH . Cystic fibrosis transmembrane conductance regulator (CFTR) protein is selectively expressed in ciliated airway epithelial cells. Am Rev Respir Dis 1993;147:Suppl:A26-A26 abstract.
Web of Science37
Johnson LG ,Boyles SE ,Wilson J ,Boucher RC . Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995;95:1377-1382
CrossRef | Web of Science | Medline38
Wilson JM ,Engelhardt JF ,Grossman M ,Simon RH ,Yang Y . Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a phase I trial. Hum Gene Ther 1994;5:501-519
CrossRef | Web of Science | Medline39
Johnson LG, Pickles RJ, Boyles SE, et al. In vitro assessment of variables affecting the efficiency and efficacy of adenovirus-mediated gene transfer to cystic fibrosis airway epithelia. Hum Gene Ther (in press).
40
Johnson LG ,Olsen JC ,Sarkadi B ,Moore KL ,Swanstrom R ,Boucher RC . Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-25
CrossRef | Web of Science | Medline41
Naclerio RM ,Proud D ,Lichtenstein LM , et al. Kinins are generated during experimental rhinovirus colds. J Infect Dis 1988;157:133-142
CrossRef | Web of Science | Medline42
Henderson FW ,Dubovi EJ ,Harder S ,Seal E Jr ,Graham D . Experimental rhinovirus infection in human volunteers exposed to ozone. Am Rev Respir Dis 1988;137:1124-1128
Web of Science | Medline43
Piedimonte G ,Pickles RJ ,Lehmann JR ,Costa DL ,Boucher RC . Replication-deficient adenoviral vector for gene therapy exhibits a strong potentiating effect on airway neurogenic inflammation. Pediatr Pulmonol 1995;12:224-224 abstract.44
Bateman ED ,Hayashi S ,Kuwano K ,Wilke TA ,Hogg JC . Latent adenoviral infection in follicular bronchiectasis. Am J Respir Crit Care Med 1995;151:170-176
Web of Science | Medline45
Caplen NJ ,Alton EWFW ,Middleton PG , et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995;1:39-46
CrossRef | Web of Science | Medline
- Citing Articles (183)
Citing Articles
1
Huibi Cao, Robert S. Molday, Jim Hu. (2011) Gene therapy: light is finally in the tunnel. Protein & Cell 2:12, 973-989
CrossRef2
Isik Turker, Tomohiko Ai. (2011) Gene therapy for AF: A dream too far?. Heart Rhythm 8:11, 1730-1731
CrossRef3
Dahai Jiang, Aliasger K. Salem. (2011) Optimized dextran–polyethylenimine conjugates are efficient non-viral vectors with reduced cytotoxicity when used in serum containing environments. International Journal of Pharmaceutics
CrossRef4
Tao Geng, Yihong Zhan, Jun Wang, Chang Lu. (2011) Transfection of cells using flow-through electroporation based on constant voltage. Nature Protocols 6:8, 1192-1208
CrossRef5
Yuliang Xiao, Jiangfeng Zhu, Lianyin Zheng. 2011. Application of Chitosan-Based Gels in Pharmaceuticals. , 315-338.
CrossRef6
Yong Sun, Shuai Zhang, Xi Peng, Zhenyu Gong, Xiaolu Li, Zhiqiang Yuan, Ying Li, Dawei Zhang, Yizhi Peng. (2011) Preparation, characterization and transfection efficacy of chitosan nanoparticles containing the intestinal trefoil factor gene. Molecular Biology Reports
CrossRef7
Basma M Ibrahim, Michael D Tsifansky, Yan Yang, Yoon Yeo. (2011) Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. Expert Opinion on Drug Delivery 8:4, 451-466
CrossRef8
Corinna Pfeifer, Anne Himmel, Johannes-Peter Geiger, Manish K Aneja, Carsten Rudolph. (2010) Efficient, specific and targeted delivery of genes to the lung. Therapeutic Delivery 1:1, 133-148
CrossRef9
Jian Xin, Yan Luo, Ze-Feng Xia, Kai-Xiong Tao, Kai-Lin Cai, Gao-Xiong Han, Xiao-Ming Shuai, Ji-Liang Wang, Han-Song Du, Guo-Bin Wang. (2010) Development of a magnetite-gene complex for gene transfection. Frontiers of Medicine in China 4:2, 241-246
CrossRef10
Andrew M. Jones, Jennifer M. Helm. (2009) Emerging Treatments in Cystic Fibrosis. Drugs 69:14, 1903-1910
CrossRef11
Niklas Arnberg. (2009) Adenovirus receptors: implications for tropism, treatment and targeting. Reviews in Medical Virology 19:3, 165-178
CrossRef12
Hulda Swai, Boitumelo Semete, Lonji Kalombo, Paul Chelule, Kevin Kisich, Bob Sievers. (2009) Nanomedicine for respiratory diseases. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 1:3, 255-263
CrossRef13
Rajesh Mukthavaram, Srujan Marepally, Mahidhar Y. Venkata, Gangamodi N. Vegi, Ramakrishna Sistla, Arabinda Chaudhuri. (2009) Cationic glycolipids with cyclic and open galactose head groups for the selective targeting of genes to mouse liver. Biomaterials 30:12, 2369-2384
CrossRef14
Yuhu Song, Howard H. Lou, Julie L. Boyer, Maria P. Limberis, Luk H. Vandenberghe, Neil R. Hackett, Philip L. Leopold, James M. Wilson, Ronald G. Crystal. (2009) Functional Cystic Fibrosis Transmembrane Conductance Regulator Expression in Cystic Fibrosis Airway Epithelial Cells by AAV6.2-Mediated Segmental Trans -Splicing. Human Gene Therapy 20:3, 267-281
CrossRef15
Uta Griesenbach, Eric W.F.W. Alton. (2009) Gene transfer to the lung: Lessons learned from more than 2 decades of CF gene therapy. Advanced Drug Delivery Reviews 61:2, 128-139
CrossRef16
Felix A Ratjen. (2009) Cystic Fibrosis: Pathogenesis and Future Treatment Strategies. Respiratory Care 54:5, 595-605
CrossRef17
Gaurang S Daftary, Hugh S Taylor. 2008. In-utero gene transfer: promises and problems. , 623-636.
CrossRef18
Terence R. Flotte. 2008. Gene Transfer in the Lung. , 509-515.
CrossRef19
F DOMANN. 2008. Detection of Pulmonary Gene Transfer Using Iodide-124/Positron Emission Tomography. , 281-293.
CrossRef20
A R Price, M P Limberis, J M Wilson, S L Diamond. (2007) Pulmonary delivery of adenovirus vector formulated with dexamethasone–spermine facilitates homologous vector re-administration. Gene Therapy 14:22, 1594-1604
CrossRef21
Ellen A. M. Schenk-Braat, Marjolein M. K. B. van Mierlo, Gerard Wagemaker, Chris H. Bangma, Leonie C. M. Kaptein. (2007) An inventory of shedding data from clinical gene therapy trials. The Journal of Gene Medicine 9:10, 910-921
CrossRef22
Tim WR Lee, Kevin W Southern, Tim WR Lee. 2007. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. .
CrossRef23
Edward A. Burton, David J. Fink, Joseph C. Glorioso. 2006. Vectors and Gene Therapy. .
CrossRef24
Massimo Cristofanilli, Savitri Krishnamurthy, Laura Guerra, Kristine Broglio, Banu Arun, Daniel J. Booser, Kerstin Menander, Jill Van Wart Hood, Vicente Valero, Gabriel N. Hortobagyi. (2006) A nonreplicating adenoviral vector that contains the wild-typep53 transgene combined with chemotherapy for primary breast cancer. Cancer 107:5, 935-944
CrossRef25
Timothy P. O'Connor, Ronald G. Crystal. (2006) Genetic medicines: treatment strategies for hereditary disorders. Nature Reviews Genetics 7:4, 261-276
CrossRef26
T Lee, KW Southern, Tim Lee. 2006. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. .
CrossRef27
Lawrence S Young, Peter F Searle, David Onion, Vivien Mautner. (2006) Viral gene therapy strategies: from basic science to clinical application. The Journal of Pathology 208:2, 299-318
CrossRef28
Bruce K. Rubin. (2006) Other medications for aerosol delivery. Paediatric Respiratory Reviews 7, S76-S79
CrossRef29
Marina Ulanova, Alan D Schreiber, A Dean Befus. (2006) The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases. BioDrugs 20:1, 1-11
CrossRef30
John W. Wiseman, Emily S. Scott, Paul A. Shaw, William H. Colledge. (2005) Enhancement of gene delivery to human airway epithelial cellsin vitro using a peptide from the polyoma virus protein VP1. The Journal of Gene Medicine 7:6, 759-770
CrossRef31
Gang Niu, Kimberly J. Krager, Michael M. Graham, Richard D. Hichwa, Frederick E. Domann. (2005) Noninvasive radiological imaging of pulmonary gene transfer and expression using the human sodium iodide symporter. European Journal of Nuclear Medicine and Molecular Imaging 32:5, 534-540
CrossRef32
Stephen Tate, Stuart Elborn. (2005) Progress towards gene therapy for cystic fibrosis. Expert Opinion on Drug Delivery 2:2, 269-280
CrossRef33
Michael W. Konstan, Pamela B. Davis, Jeffrey S. Wagener, Kathleen A. Hilliard, Robert C. Stern, Laura J.H. Milgram, Tomasz H. Kowalczyk, Susannah L. Hyatt, Tamara L. Fink, Christopher R. Gedeon, Sharon M. Oette, Jennifer M. Payne, Osman Muhammad, Assem G. Ziady, Robert C. Moen, Mark J. Cooper. (2004) Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution. Human Gene Therapy 0:0, 041210060115001
CrossRef34
Stephan Hermening, Sebastian Kügler, Mathias Bähr, Stefan Isenmann. (2004) Increased protein expression from adenoviral shuttle plasmids and vectors by insertion of a small chimeric intron sequence. Journal of Virological Methods 122:1, 73-77
CrossRef35
Michael W. Konstan, Pamela B. Davis, Jeffrey S. Wagener, Kathleen A. Hilliard, Robert C. Stern, Laura J.H. Milgram, Tomasz H. Kowalczyk, Susannah L. Hyatt, Tamara L. Fink, Christopher R. Gedeon, Sharon M. Oette, Jennifer M. Payne, Osman Muhammad, Assem G. Ziady, Robert C. Moen, Mark J. Cooper. (2004) Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution. Human Gene Therapy 15:12, 1255-1269
CrossRef36
Daniel A. Muruve. (2004) The Innate Immune Response to Adenovirus Vectors. Human Gene Therapy 15:12, 1157-1166
CrossRef37
M Ravi Kumar, Gary Hellermann, Richard F Lockey, Shyam S Mohapatra. (2004) Nanoparticle-mediated gene delivery: state of the art. Expert Opinion on Biological Therapy 4:8, 1213-1224
CrossRef38
Jennifer L Harcourt, Larry J Anderson, Wayne Sullender, Ralph A Tripp. (2004) Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles. Vaccine 22:17-18, 2248-2260
CrossRef39
Bharat Kumar Majeti, Rajkumar Sunil Singh, Sudheer Kumar Yadav, Surendar Reddy Bathula, Sistla Ramakrishna, Prakash Vamanrao Diwan, Surkara Sakunthala Madhavendra, Arabinda Chaudhuri. (2004) Enhanced Intravenous Transgene Expression in Mouse Lung Using Cyclic-Head Cationic Lipids. Chemistry & Biology 11:4, 427-437
CrossRef40
Freedman, Steven D., Blanco, Paola G., Zaman, Munir M., Shea, Julie C., Ollero, Mario, Hopper, Isabel K., Weed, Deborah A., Gelrud, Andres, Regan, Meredith M., Laposata, Michael, Alvarez, Juan G., O'Sullivan, Brian P., . (2004) Association of Cystic Fibrosis with Abnormalities in Fatty Acid Metabolism. New England Journal of Medicine 350:6, 560-569
Full Text41
Gustavo Pradilla, Tony Azzam, Paul P Wang, Abraham J Domb, Henry Brem. (2003) Gene therapy for malignant brain tumors. Expert Review of Neurotherapeutics 3:5, 685-701
CrossRef42
Larry G. Johnson, Miriam K. Vanhook, Carolyn B. Coyne, Najwa Haykal-Coates, Stephen H. Gavett. (2003) Safety and Efficiency of Modulating Paracellular Permeability to Enhance Airway Epithelial Gene Transfer In Vivo. Human Gene Therapy 14:8, 729-747
CrossRef43
Radi Hejazi, Mansoor Amiji. (2003) Chitosan-based gastrointestinal delivery systems. Journal of Controlled Release 89:2, 151-165
CrossRef44
Ryan A. Driskell, John F. Engelhardt. (2003) C
URRENT STATUS OF GENE THERAPY FOR INHERITED LUNG DISEASES . Annual Review of Physiology 65:1, 585-612
CrossRef45
Felix Ratjen, Gerd Döring. (2003) Cystic fibrosis. The Lancet 361:9358, 681-689
CrossRef46
Stefano Ferrari, Duncan M Geddes, Eric W.F.W Alton. (2002) Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Advanced Drug Delivery Reviews 54:11, 1373-1393
CrossRef47
Yang Li, Daniel?A. Muruve, Robert?G. Collins, Samuel?S. Lee, Paul Kubes. (2002) The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. European Journal of Immunology 32:12, 3443-3452
CrossRef48
Daren L. Knoell, Jill M. Kolesar. 2002. Gene Therapy. , 367-378.
CrossRef49
Paul Waszak, Marie-Laure Franco-Montoya, Marie-Paule Jacob, Isabelle Deprez, Micheline Levame, Chantal Lafuma, Alain Harf, Christophe Delacourt. (2002) Effect of Intratracheal Adenoviral Vector Administration on Lung Development in Newborn Rats. Human Gene Therapy 13:15, 1873-1885
CrossRef50
JOANNE T. DOUGLAS. (2002) Targeted adenoviral vectors. Molecular Physics 100:19, 3075-3091
CrossRef51
Rainer Buscher, Katrin Eilmes, Hartmut Grasemann, Brian Torres, Nicola Knauer, Karin Sroka, Paul Insel, Felix Ratjen. (2002) Pharmacogenetics 12:5, 347-353
CrossRef52
Max W. Sung, Shu-Hsia Chen, Swan N. Thung, David Y. Zhang, Tian-Gui Huang, John P. Mandeli, Savio L.C. Woo. (2002) Intratumoral Delivery of Adenovirus-Mediated Interleukin-12 Gene in Mice with Metastatic Cancer in the Liver. Human Gene Therapy 13:6, 731-743
CrossRef53
Gloria P. Bowen, Stephanie L. Borgland, Mindy Lam, Towia A. Libermann, Norman C.W. Wong, Daniel A. Muruve. (2002) Adenovirus Vector-Induced Inflammation: Capsid-Dependent Induction of the C-C Chemokine RANTES Requires NF- κ B. Human Gene Therapy 13:3, 367-379
CrossRef54
Laurence Vaysse, Christine Guillaume, Ingrid Burgelin, Philippe Gorry, Claude Férec, Benoı̂t Arveiler. (2002) Proteolipidic Vectors for Gene Transfer to the Lung. Biochemical and Biophysical Research Communications 290:5, 1489-1498
CrossRef55
L. Blanckwood, D. J. Argyle. (2002) Feline hyperthyroidism: advances towards novel molecular therapeutics. Journal of Small Animal Practice 43:2, 58-66
CrossRef56
James Wilson, Nelson Wivel. 2002. Gene Therapy. .
CrossRef57
Yukiko Arimoto, Hiroshi Nagata, Naohisa Isegawa, Keiichiro Kumahara, Kyoko Isoyama, Akiyoshi Konno, Hiroshi Shirasawa. (2002) In vivo Expression of Adenovirus-mediated lacZ Gene in Murine Nasal Mucosa. Acta Oto-laryngologica 122:6, 627-633
CrossRef58
Ben-Gary Harvey, Jaman Maroni, Kelley A. O'Donoghue, Karen W. Chu, Jolene C. Muscat, Allison L. Pippo, Connie E. Wright, Charleen Hollmann, Juan P. Wisnivesky, Paul D. Kessler, Henrik S. Rasmussen, Todd K. Rosengart, Ronald G. Crystal. (2002) Safety of Local Delivery of Low- and Intermediate-Dose Adenovirus Gene Transfer Vectors to Individuals with a Spectrum of Morbid Conditions. Human Gene Therapy 13:1, 15-63
CrossRef59
Cathryn Mah, Barry J. Byrne, Terence R. Flotte. (2002) Virus-Based Gene Delivery Systems. Clinical Pharmacokinetics 41:12, 901-911
CrossRef60
DANUTA BALICKI, ERNEST BEUTLER. (2002) Gene Therapy of Human Disease. Medicine 81:1, 69-86
CrossRef61
YUZO KODAMA, YASUHIRO SETOGUCHI, YOSHINOSUKE FUKUCHI. (2001) Infection of replication-deficient adenoviral vector enhances interleukin-8 production in small airway epithelial cells more than in large airway epithelial cells. Respirology 6:4, 271-279
CrossRef62
Gaurang S. Daftary, Hugh S. Taylor. (2001) Efficient Liposome-Mediated Gene Transfection and Expression in the Intact Human Uterus. Human Gene Therapy 12:17, 2121-2127
CrossRef63
Gerrit Borchard. (2001) Chitosans for gene delivery. Advanced Drug Delivery Reviews 52:2, 145-150
CrossRef64
M.L. Aitken, R.B. Moss, D.A. Waltz, M.E. Dovey, M.R. Tonelli, S.C. McNamara, R.L. Gibson, B.W. Ramsey, B.J. Carter, T.C. Reynolds. (2001) A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease. Human Gene Therapy 12:15, 1907-1916
CrossRef65
Derek S. Wheeler, Hector R. Wong. (2001) The impact of molecular biology on the practice of pediatric critical care medicine. Pediatric Critical Care Medicine 2:4, 299-310
CrossRef66
Patricia M. Joseph, Brian P. O'Sullivan, Allen Lapey, Henry Dorkin, Joseph Oren, Rosemary Balfour, Michael A. Perricone, Mireille Rosenberg, Samuel C. Wadsworth, Alan E. Smith, Judith A. St. George, David P. Meeker. (2001) Aerosol and Lobar Administration of a Recombinant Adenovirus to Individuals with Cystic Fibrosis. I. Methods, Safety, and Clinical Implications. Human Gene Therapy 12:11, 1369-1382
CrossRef67
Michael A. Perricone, James E. Morris, Karen Pavelka, Malinda S. Plog, Brian P. O'Sullivan, Patricia M. Joseph, Henry Dorkin, Allen Lapey, Rosemary Balfour, David P. Meeker, Alan E. Smith, Samuel C. Wadsworth, Judith A. St. George. (2001) Aerosol and Lobar Administration of a Recombinant Adenovirus to Individuals with Cystic Fibrosis. II. Transfection Efficiency in Airway Epithelium. Human Gene Therapy 12:11, 1383-1394
CrossRef68
Christopher L. Wu, Mary G. Garry, Raymond A. Zollo, Jay Yang. (2001) Gene Therapy for the Management of Pain. Anesthesiology 94:6, 1119-1132
CrossRef69
Clare E. Thomas, Evelyn Abordo-Adesida, Tricia C. Maleniak, Daniel Stone, Christian A. Gerdes, Pedro R. Lowenstein. 2001. Gene Transfer into Rat Brain Using Adenoviral Vectors. .
CrossRef70
Q. Chu, J.A. St. George, M. Lukason, S.H. Cheng, R.K. Scheule, S.J. Eastman. (2001) EGTA Enhancement of Adenovirus-Mediated Gene Transfer to Mouse Tracheal Epithelium in Vivo. Human Gene Therapy 12:5, 455-467
CrossRef71
Xiao-Yan Wen, Yahong Bai, A. Keith Stewart. (2001) Adenovirus-Mediated Human Endostatin Gene Delivery Demonstrates Strain-Specific Antitumor Activity and Acute Dose-Dependent Toxicity in Mice. Human Gene Therapy 12:4, 347-358
CrossRef72
Emily S. Scott, John W. Wiseman, Martin J. Evans, William H. Colledge. (2001) Enhanced gene delivery to human airway epithelial cells using an integrin-targeting lipoplex. The Journal of Gene Medicine 3:2, 125-134
CrossRef73
Richard Heller, Jan Schultz, M. Lee Lucas, Mark J. Jaroszeski, Loree C. Heller, Richard A. Gilbert, Karin Moelling, Claude Nicolau. (2001) Intradermal Delivery of Interleukin-12 Plasmid DNA by in vivo Electroporation. DNA and Cell Biology 20:1, 21-26
CrossRef74
Stéphanie Lerondel, Alain Le Pape, Claude Sené, Laurence Faure, Serge Bernard, Patrice Diot, Elena Nicolis, Majid Mehtali, Monika Lusky, Giulio Cabrini, Andrea Pavirani. (2001) Radioisotopic Imaging Allows Optimization of Adenovirus Lung Deposition for Cystic Fibrosis Gene Therapy. Human Gene Therapy 12:1, 1-11
CrossRef75
Duncan Geddes. (2001) Perspectives in gene therapy. Pediatric Pulmonology 26:S23, 97-99
CrossRef76
Brian Bigger, Charles Coutelle. (2001) Perspectives on Gene Therapy for Cystic Fibrosis Airway Disease. BioDrugs 15:9, 615-634
CrossRef77
Duncan Geddes. (2001) Perspectives in gene therapy. Pediatric Pulmonology 32:S23, 97-99
CrossRef78
Mark R. Tonelli, Moira L. Aitken. (2001) New and Emerging Therapies for Pulmonary Complications of Cystic Fibrosis. Drugs 61:10, 1379-1385
CrossRef79
Mark E. Hutchin, Raymond J. Pickles, Wendell G. Yarbrough. (2000) Efficiency of Adenovirus-Mediated Gene Transfer to Oropharyngeal Epithelial Cells Correlates with Cellular Differentiation and Human Coxsackie and Adenovirus Receptor Expression. Human Gene Therapy 11:17, 2365-2375
CrossRef80
Lloyd J. Edwards. (2000) Modern statistical techniques for the analysis of longitudinal data in biomedical research. Pediatric Pulmonology 30:4, 330-344
CrossRef81
Terry L. Noah, Susanne Becker. (2000) Chemokines in Nasal Secretions of Normal Adults Experimentally Infected with Respiratory Syncytial Virus. Clinical Immunology 97:1, 43-49
CrossRef82
Wolfgang Walther, Ulrike Stein. (2000) Viral Vectors for Gene Transfer. Drugs 60:2, 249-271
CrossRef83
Chris Kitson, Eric Alton. (2000) Gene therapy for cystic fibrosis. Expert Opinion on Investigational Drugs 9:7, 1523-1535
CrossRef84
(2000) A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination with Escalating Doses of Ganciclovir in Patients with Cutaneous Metastatic Malignant Melanoma. Human Gene Therapy 11:3, 487-503
CrossRef85
Takashi Suda, Bassem N. Mora, Franco D’Ovidio, Jonas A. Cooper, Masafumi Hiratsuka, Wanjiang Zhang, T. Mohanakumar, G.Alexander Patterson. (2000) In vivo adenovirus-mediated endothelial nitric oxide synthase gene transfer ameliorates lung allograft ischemia-reperfusion injury. The Journal of Thoracic and Cardiovascular Surgery 119:2, 297-304
CrossRef86
Jonathan B. Zuckerman, Cynthia B. Robinson, Karen S. M, Richard Shell, Thomas J. Sferra, Narendra Chirmule, Susan A. Magosin, Kathleen J. Propert, Elsbeth C. Brown-Parr, Joseph V. Hughes, John Tazelaar, Colleen Baker, Mitchell J. Goldman, James M. Wilson. (1999) A Phase I Study of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to a Lung Segment of Individuals with Cystic Fibrosis. Human Gene Therapy 10:18, 2973-2985
CrossRef87
Chandrika Kurpad, Pinku Mukherjee, Xu-Shan Wang, Selvarangan Ponnazhagan, Linglin Li, Mervin C. Yoder, Arun Srivastava. (1999) Adeno-Associated Virus 2-Mediated Transduction and Erythroid Lineage-Restricted Expression from Parvovirus B19p6 Promoter in Primary Human Hematopoietic Progenitor Cells. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 8:6, 585-592
CrossRef88
Edmund Y. Yang, Alan W. Flake, N. Scott Adzick. (1999) Prospects for fetal gene therapy. Seminars in Perinatology 23:6, 524-534
CrossRef89
DAVID T. CURIEL. (1999) Strategies to Adapt Adenoviral Vectors for Targeted Delivery. Annals of the New York Academy of Sciences 886:1 ANTICANCER MO, 158-171
CrossRef90
Ronald G. Crystal. (1999) Bad for cats, good for humans? Modified feline immunodeficiency virus for gene therapy. Journal of Clinical Investigation 104:11, 1491-1493
CrossRef91
Ben-Gary Harvey, Stefan Worgall, Scott Ely, Philip L. Leopold, Ronald G. Crystal. (1999) Cellular Immune Responses of Healthy Individuals to Intradermal Administration of an E1 - E3 - Adenovirus Gene Transfer Vector. Human Gene Therapy 10:17, 2823-2837
CrossRef92
Ben-Gary Harvey, Philip L. Leopold, Neil R. Hackett, Tina M. Grasso, P. Mickey Williams, Ayly L. Tucker, Robert J. Kaner, Barbara Ferris, Igor Gonda, Theresa D. Sweeney, Ramachandran Ramalingam, Imre Kovesdi, Steven Shak, Ronald G. Crystal. (1999) Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. Journal of Clinical Investigation 104:9, 1245-1255
CrossRef93
Jolanta F. Kukowska-Latallo, Chunling Chen, Jon Eichman, Anna U. Bielinska, James R. Baker. (1999) Enhancement of Dendrimer-Mediated Transfection Using Synthetic Lung Surfactant Exosurf Neonatal in Vitro. Biochemical and Biophysical Research Communications 264:1, 253-261
CrossRef94
Rita Shah, Rahul M. Jindal. (1999) Stable transfection of rat preproinsulin II gene into rat hematopoietic stem cells via recombinant adeno-associated virus. Life Sciences 65:20, 2041-2047
CrossRef95
Carol M. Mason, Steve Nelson. (1999) PULMONARY HOST DEFENSES. Clinics in Chest Medicine 20:3, 475-488
CrossRef96
Steven W. Dow, Jurgen Schwarze, Timothy D. Heath, Terry A. Potter, Erwin W. Gelfand. (1999) Systemic and Local Interferon gamma Gene Delivery to the Lungs for Treatment of Allergen-Induced Airway Hyperresponsiveness in Mice. Human Gene Therapy 10:12, 1905-1914
CrossRef97
W.T. Godbey, Kenneth K. Wu, Antonios G. Mikos. (1999) Poly(ethylenimine) and its role in gene delivery. Journal of Controlled Release 60:2-3, 149-160
CrossRef98
Clare Sansom. (1999) A step towards gene therapy for CF. Molecular Medicine Today 5:7, 279
CrossRef99
David L Ennist. (1999) Gene therapy for lung disease. Trends in Pharmacological Sciences 20:6, 260-266
CrossRef100
Daniel A. Muruve, Melissa J. Barnes, Isaac E. Stillman, Towia A. Libermann. (1999) Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in Vivo. Human Gene Therapy 10:6, 965-976
CrossRef101
Roswitha Gropp, Michaela Frye, Thomas O.F. Wagner, Joachim Bargon. (1999) Epithelial Defensins Impair Adenoviral Infection: Implication for Adenovirus-Mediated Gene Therapy. Human Gene Therapy 10:6, 957-964
CrossRef102
Theodore J. Standiford, Jodi M. Wilkowski, Thomas H. Sisson, Noboru Hattori, Borna Mehrad, Kathy A. Bucknell, Thomas A. Moore. (1999) Intrapulmonary Tumor Necrosis Factor Gene Therapy Increases Bacterial Clearance and Survival in Murine Gram-Negative Pneumonia. Human Gene Therapy 10:6, 899-909
CrossRef103
EWFW Alton, M Stern, R Farley, A Jaffe, SL Chadwick, J Phillips, J Davies, SN Smith, J Browning, MG Davies, ME Hodson, SR Durham, D Li, PK Jeffery, M Scallan, R Balfour, SJ Eastman, SH Cheng, AE Smith, D Meeker, DM Geddes. (1999) Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. The Lancet 353:9157, 947-954
CrossRef104
Franklin Cerasoli. (1999) Emerging therapeutic targets in asthma: immunomodulatory cytokines and their delivery. Expert Opinion on Therapeutic Targets 3:1, 27-39
CrossRef105
John H. Lee, Joseph Zabner, Michael J. Welsh. (1999) Delivery of an Adenovirus Vector in a Calcium Phosphate Coprecipitate Enhances the Therapeutic Index of Gene Transfer to Airway Epithelia. Human Gene Therapy 10:4, 603-613
CrossRef106
Richard C. Boucher. (1999) Status of gene therapy for cystic fibrosis lung disease. Journal of Clinical Investigation 103:4, 441-445
CrossRef107
John A. Wagner, Anna H. Messner, Mary Lynn Moran, Richard Daifuku, Keisuke Kouyama, Julie K. Desch, Sara Manley, Alexander M. Norbash, Carol K. Conrad, Sandra Friborg, Thomas Reynolds, William B. Guggino, Richard B. Moss, Barrie J. Carter, Jeffrey J. Wine, Terence R. Flotte, Phyllis Gardner. (1999) Safety and Biological Efficacy of an Adeno-Associated Virus Vector-Cystic Fibrosis Transmembrane Regulator (AAV-CFTR) in the Cystic Fibrosis Maxillary Sinus. The Laryngoscope 109:2, 266-274
CrossRef108
Dariusz C Górecki. (1999) Gene therapy: prospects and problems. Expert Opinion on Emerging Drugs 4:1, 247-261
CrossRef109
Shinji Teramoto, Hideki Ito, Yasuyoshi Ouchi. (1999) Variables Affecting the Transduction Efficiency of Adenovirus Vectors in Bovine Aortic Endothelial Cells. Thrombosis Research 93:1, 35-42
CrossRef110
David W. Parsons, Barbara R. Grubb, Larry G. Johnson, Richard C. Boucher. (1998) Enhanced In Vivo Airway Gene Transfer via Transient Modification of Host Barrier Properties with a Surface-Active Agent. Human Gene Therapy 9:18, 2661-2672
CrossRef111
Scott M. Graham. (1998) Gene therapy for cystic fibrosis: perspectives for the otolaryngologist. Clinical Otolaryngology and Allied Sciences 23:6, 481-483
CrossRef112
Christine Guillaume-Gable, Virginie Floch, Bernard Mercier, Marie-Pierre Audrézet, Eric Gobin, Gwenaëlle Le Bolc'H, Jean-Jacques Yaouanc, Jean-Claude Clément, Hervé Des Abbayes, Jean-Paul Leroy, Vincent Morin, Claude Férec. (1998) Cationic Phosphonolipids as Nonviral Gene Transfer Agents in the Lungs of Mice. Human Gene Therapy 9:16, 2309-2319
CrossRef113
Kazuhisa Otake, David L. Ennist, Kevin Harrod, Bruce C. Trapnell. (1998) Nonspecific Inflammation Inhibits Adenovirus-Mediated Pulmonary Gene Transfer and Expression Independent of Specific Acquired Immune Responses. Human Gene Therapy 9:15, 2207-2222
CrossRef114
Brigitte Sternberg, Keelung Hong, Weiwen Zheng, Demetrios Papahadjopoulos. (1998) Ultrastructural characterization of cationic liposome-DNA complexes showing enhanced stability in serum and high transfection activity in vivo. Biochimica et Biophysica Acta (BBA) - Biomembranes 1375:1-2, 23-35
CrossRef115
Katherine L. Molnar-Kimber, Daniel H. Sterman, Michael Chang, Eugen H. Kang, Mohammed ElBash, Michael Lanuti, Ashraf Elshami, Karen Gelfand, James M. Wilson, Larry R. Kaiser, Steven M. Albelda. (1998) Impact of Preexisting and Induced Humoral and Cellular Immune Responses in an Adenovirus-Based Gene Therapy Phase I Clinical Trial for Localized Mesothelioma. Human Gene Therapy 9:14, 2121-2133
CrossRef116
Martin Schuler, Christoph Rochlitz, Jo Ann Horowitz, Jens Schlegel, André P. Perruchoud, Friedrich Kommoss, Christoph T. Bolliger, Hans-Ulrich Kauczor, Peter Dalquen, Mary Ann Fritz, Steve Swanson, Richard Herrmann, Christoph Huber. (1998) A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer. Human Gene Therapy 9:14, 2075-2082
CrossRef117
Carol G. Shores, Wendell G. Yarbrough. (1998) Three-dimensional xenograft model of dysplastic human laryngeal mucosa. The Laryngoscope 108:9, 1358-1362
CrossRef118
Cynthia B. Robinson. (1998) IS DNA DESTINY?. Clinics in Chest Medicine 19:3, 527-534
CrossRef119
Jeffrey Bonadio, Steven A Goldstein, Robert J Levy. (1998) Gene therapy for tissue repair and regeneration. Advanced Drug Delivery Reviews 33:1-2, 53-69
CrossRef120
Patricia L. Chang, Kelly MacMillan Bowie. (1998) Development of engineered cells for implantation in gene therapy. Advanced Drug Delivery Reviews 33:1-2, 31-43
CrossRef121
Wanda K. O'Neal, Heshan Zhou, Núria Morral, Estuardo Aguilar-Cordova, Joseph Pestaner, Claire Langston, Benjamin Mull, Yufen Wang, Arthur L. Beaudet, Brendan Lee. (1998) Toxicological Comparison of E2a-Deleted and First-Generation Adenoviral Vectors Expressing α 1 -Antitrypsin after Systemic Delivery. Human Gene Therapy 9:11, 1587-1598
CrossRef122
Johanne M. Kaplan, Sarah E. Pennington, Judith A. St. George, Lisa A. Woodworth, Al Fasbender, John Marshall, Seng H. Cheng, Samuel C. Wadsworth, Richard J. Gregory, Alan E. Smith. (1998) Potentiation of Gene Transfer to the Mouse Lung by Complexes of Adenovirus Vector and Polycations Improves Therapeutic Potential. Human Gene Therapy 9:10, 1469-1479
CrossRef123
Colton A. Smith, Linda S. Woodruff, Cliona Rooney, Geoffrey R. Kitchingman. (1998) Extensive Cross-Reactivity of Adenovirus-Specific Cytotoxic T Cells. Human Gene Therapy 9:10, 1419-1427
CrossRef124
Robert J. Desnick, Edward H. Schuchman. (1998) Gene therapy for genetic diseases. Pediatrics International 40:3, 191-203
CrossRef125
Daniel H. Sterman, Joseph Treat, Leslie A. Litzky, Kunjlata M. Amin, Laura Coonrod, Katherine Molnar-Kimber, Adri Recio, Linda Knox, James M. Wilson, Steven M. Albelda, Larry R. Kaiser. (1998) Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma. Human Gene Therapy 9:7, 1083-1092
CrossRef126
K.W Leong, H.-Q Mao, V.L Truong-Le, K Roy, S.M Walsh, J.T August. (1998) DNA-polycation nanospheres as non-viral gene delivery vehicles. Journal of Controlled Release 53:1-3, 183-193
CrossRef127
Yulong Zhang, Qinshi Jiang, Lorita Dudus, James R. Yankaskas, John F. Engelhardt. (1998) Vector-Specific Complementation Profiles of Two Independent Primary Defects in Cystic Fibrosis Airways. Human Gene Therapy 9:5, 635-648
CrossRef128
Mien-Chie Hung, Joe Yujiao Chang, Xiangming Xing. (1998) Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. Advanced Drug Delivery Reviews 30:1-3, 219-227
CrossRef129
Jeffrey M Isner. (1998) Arterial gene transfer of naked DNA for therapeutic angiogenesis: early clinical results. Advanced Drug Delivery Reviews 30:1-3, 185-197
CrossRef130
Duncan Geddes, Eric Alton. (1998) Cystic fibrosis clinical trials. Advanced Drug Delivery Reviews 30:1-3, 205-217
CrossRef131
Changbin Qiu, Mary Beth de Young, Aloke Finn, David A. Dichek. (1998) Cationic Liposomes Enhance Adenovirus Entry via a Pathway Independent of the Fiber Receptor and α v -Integrins. Human Gene Therapy 9:4, 507-520
CrossRef132
Diane Holditch-Davis, Lloyd J. Edwards, Ronald W. Helms. (1998) Modeling Development of Sleep–Wake Behaviors: I. Using the Mixed General Linear Model fn1fn1We wish to thank Carol Shaw, Nancy Steelman, Deborah Lee, Di Liu, Debra B. Miller, and Charlene Garrett for technical assistance and Annette Frauman for editorial assistance. The preparation of this paper was supported by Grant NR01894 from the National Institute for Nursing Research, National Institutes of Health.. Physiology & Behavior 63:3, 311-318
CrossRef133
Philippe M. Frossard, Emmanuelle Girodon, Kenneth P. Dawson, Nada Ghanem, François Plassa, Gilles G. Lestringant, Michel Goossens. (1998) Identification of cystic fibrosis mutations in the United Arab Emirates. Human Mutation 11:5, 412-413
CrossRef134
Motoyoshi Suzuki, Ravi N. Singh, Ronald G. Crystal. (1998) Pharmacological expression in rat hepatocytes of a gene transferred by an adenovirus vector enabled by a chimeric promoter containing multiple cyclic adenosine monophosphate response elements. Hepatology 27:1, 160-165
CrossRef135
Carolina V. Arancibia-C??rcamo, H. Barbaros Oral, Dorian O. Haskard, D. Frank P. Larkin, Andrew J.T. George. (1998) LIPOADENOFECTION-MEDIATED GENE DELIVERY TO THE CORNEAL ENDOTHELIUM. Transplantation 65:1, 62-67
CrossRef136
Pallav L Shah. (1998) Ongoing planned clinical trials investigating the pulmonary management of cystic fibrosis. Expert Opinion on Investigational Drugs 7:1, 91-98
CrossRef137
Guadalupe Bilbao, Jesús Gómez-Navarro, Juan Luis Contreras, David T Curiel. (1997) Advances in adenoviral vectors for cancer gene therapy. Expert Opinion on Therapeutic Patents 7:12, 1427-1446
CrossRef138
Duane A. Sewell, Daqing Li, Ling Duan, Mary R. Schwartz, Bert W. O'Malley. (1997) Optimizing Suicide Gene Therapy for Head and Neck Cancer. The Laryngoscope 107:11, 1490-1495
CrossRef139
Raymond J Pickles. (1997) Towards a gene therapy for cystic fibrosis lung disease. Expert Opinion on Investigational Drugs 6:10, 1459-1463
CrossRef140
Darryl S. Reed, Pedro Romero, Donata Rimoldi, Jean-Charles Cerottini, Jerome Schaack, C. Victor Jongeneel. (1997) Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen. International Journal of Cancer 72:6, 1045-1055
CrossRef141
Andrea Pavirani. (1997) The therapeutic potential of the human cystic fibrosis transmembrane conductance regulator gene. Expert Opinion on Investigational Drugs 6:9, 1187-1192
CrossRef142
James J. Yoo, Anthony Atala. (1997) A Novel Gene Delivery System Using Urothelial Tissue Engineered Neo-Organs. The Journal of Urology 158:3, 1066-1070
CrossRef143
Christine H. Le, A. Graham Nicolson, Alejandro Morales, K. Lea Sewell. (1997) Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor α receptor gene. Arthritis & Rheumatism 40:9, 1662-1669
CrossRef144
Florence Dupuit, Thierry Chinet, Jean-Marie Zahm, Denis Pierrot, Jocelyne Hinnrasky, Herve Kaplan, Noël Bonnet, Edith Puchelle. (1997) Induction of a cAMP–Stimulated Chloride Secretion in Regenerating Poorly Differentiated Airway Epithelial Cells by Adenovirus-Mediated CFTR Gene Transfer. Human Gene Therapy 8:12, 1439-1450
CrossRef145
Shinji Teramoto, Takeshi Matsuse, Eijiro Ohga, Takahide Nagase, Yoshinosuke Fukucrui, Yasuyoshi Ouchi. (1997) Kinetics of adenovirus-mediated gene transfer to human lung fibroblasts. Life Sciences 61:9, 891-897
CrossRef146
ZHONGYUN DONG, XIULAN YANG, ISAIAH J. FIDLER. (1997) Neutralization of Endogenous Interferon-β Increases the Efficiency of Adenoviral Vector-Mediated Gene Transduction. Journal of Interferon & Cytokine Research 17:7, 401-407
CrossRef147
David S Strayer, Roland Schwarting. (1997) Recognition of normal, neoplastic, and fetal airway epithelial cell membranes by two monoclonal antibodies. Human Pathology 28:7, 840-846
CrossRef148
Vered H. Eisenberg, Joseph G. Schenker. (1997) Genetic engineering: Moral aspects and control of practice. Journal of Assisted Reproduction and Genetics 14:6, 297-316
CrossRef149
Canwen Jiang, Geoffrey Y. Akita, William H. Colledge, Rosemary A. Ratcliff, Martin J. Evans, Kathleen M. Hehir, Judith A. St. George, Samuel C. Wadsworth, Seng H. Cheng. (1997) Increased Contact Time Improves Adenovirus-Mediated CFTR Gene Transfer to Nasal Epithelium of CF Mice. Human Gene Therapy 8:6, 671-680
CrossRef150
Stern, Robert C., . (1997) The Diagnosis of Cystic Fibrosis. New England Journal of Medicine 336:7, 487-491
Full Text151
John A. Wagner, MD, PhD, Phyllis Gardner, MD. (1997) TOWARD CYSTIC FIBROSIS GENE THERAPY. Annual Review of Medicine 48:1, 203-216
CrossRef152
U. Hedin, E. Wahlberg. (1997) Gene therapy and vascular disease: Potential applications in vascular surgery. European Journal of Vascular and Endovascular Surgery 13:2, 101-111
CrossRef153
Yong Liu, Leslie C. Mounkes, H. Denny Liggitt, Carolyn S. Brown, Igor Solodin, Timothy D. Heath, Robert J. Debs. (1997) Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nature Biotechnology 15:2, 167-173
CrossRef154
PAMELA B. DAVIS, PAMELA J. BYARD, MICHAEL W. KONSTAN. (1997) Identifying Treatments That Halt Progression of Pulmonary Disease in Cystic Fibrosis. Pediatric Research 41:2, 161-165
CrossRef155
Khalid B. Islam, Pontus Blomberg, Kristina Wikström, C. I. Edvard Smith. (1997) An Academic Centre for Gene Therapy Research with Clinical Grade Manufacturing Capability. Annals of Medicine 29:6, 579-583
CrossRef156
Charles A. Mack, Wen-Ru Song, Heather Carpenter, Tom J. Wickham, Imre Kovesdi, Ben-Gary Harvey, Christopher J. Magovern, O. Wayne Isom, Todd Rosengart, Eric Falck-Pedersen, Neil R. Hackett, Ronald G. Crystal, Andrea Mastrangeli. (1997) Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype. Human Gene Therapy 8:1, 99-109
CrossRef157
J. S. Sandhu, A. Keating, N. Hozumi. (1997) Human Gene Therapy. Critical Reviews in Biotechnology 17:4, 307-326
CrossRef158
Gabriel Bellon, Laurence Michel-Calemard, Danièle Thouvenot, Véronique Jagneaux, Françoise Poitevin, Christophe Malcus, Nathalie Accart, Marie Pierre Layani, Michèle Aymard, Hélène Bernon, Jacques Bienvenu, Michael Courtney, Gerd Döring, Bernard Gilly, Robert Gilly, Didier Lamy, Hélène Levrey, Yves Morel, Christian Paulin, Frédéric Perraud, Laurence Rodillon, Claude Sené, Satta So, Françoise Touraine-Moulin, Christian Schatz, Andrea Pavirani. (1997) Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial. Human Gene Therapy 8:1, 15-25
CrossRef159
T Friedmann. (1996) The maturation of human gene therapy. Acta Paediatrica 85:11, 1261-1265
CrossRef160
Neil R. Mathias, Fumiyoshi Yamashita, Vincent H.L. Lee. (1996) Respiratory epithelial cell culture models for evaluation of ion and drug transport. Advanced Drug Delivery Reviews 22:1-2, 215-249
CrossRef161
Gail Ross, Robert Erickson, Debra Knorr, Arno G. Motulsky, Robertson Parkman, Jude Samulski, Stephen E. Straus, Brian R. Smith. (1996) Gene Therapy in the United States: A Five-Year Status Report. Human Gene Therapy 7:14, 1781-1790
CrossRef162
Edward R. Lee, John Marshall, Craig S. Siegel, Canwen Jiang, Nelson S. Yew, Margaret R. Nichols, Jennifer B. Nietupski, Robin J. Ziegler, Mathieu B. Lane, Kathryn X. Wang, Nick C. Wan, Ronald K. Scheule, David J. Harris, Alan E. Smith, Seng H. Cheng. (1996) Detailed Analysis of Structures and Formulations of Cationic Lipids for Efficient Gene Transfer to the Lung. Human Gene Therapy 7:14, 1701-1717
CrossRef163
Thilo Dörk, Manfred Stuhrmann. (1996) Molekularbiologie der Mukoviszidose. Biologie in unserer Zeit 26:5, 282-291
CrossRef164
Richard G. Vile. (1996) Gene therapy for cancer, the course ahead. Cancer and Metastasis Review 15:3, 403-410
CrossRef165
Richard C. Vile. (1996) Gene therapy for cancer-in the dock, blown off course or full speed ahead?. Cancer and Metastasis Review 15:3, 283-286
CrossRef166
Emanuela Gussoni, Yaming Wang, Cornel Fraefel, Robert G. Miller, Helen M. Blau, Alfred I. Geller, Louis M. Kunkel. (1996) A method to codetect introduced genes and their products in gene therapy protocols. Nature Biotechnology 14:8, 1012-1016
CrossRef167
Malcolm K. Brenner. (1996) Gene Transfer and Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 18:4, 322-327
CrossRef168
Mikhail V. Blagosklonny, Wafik S. El-Deiry. (1996) In vitro evaluation of ap53-expressing adenovirus as an anti-cancer drug. International Journal of Cancer 67:3, 386-392
CrossRef169
Wood, Alastair J.J., , Ramsey, Bonnie W., . (1996) Management of Pulmonary Disease in Patients with Cystic Fibrosis. New England Journal of Medicine 335:3, 179-188
Full Text170
Fred D. Ledley. (1996) “Our Study Is Man” (and Woman). Human Gene Therapy 7:10, 1193-1195
CrossRef171
Jueren Lou, Paul R. Manske, Mitsuhiro Aoki, Michael E. Joyce. (1996) Adenovirus-mediated gene transfer into tendon and tendon sheath. Journal of Orthopaedic Research 14:4, 513-517
CrossRef172
Frederick J Feuerbach, Ronald G Crystal. (1996) Progress in human gene therapy. Kidney International 49:6, 1791-1794
CrossRef173
K. J. Limbach, E. Paoletti. (1996) Non-replicating expression vectors: applications in vaccine development and gene therapy. Epidemiology and Infection 116:03, 241
CrossRef174
Raymond J. Pickles, Pierre M. Barker, Hong Ye, Richard C. Boucher. (1996) Efficient Adenovirus-Mediated Gene Transfer to Basal but Not Columnar Cells of Cartilaginous Airway Epithelia. Human Gene Therapy 7:8, 921-931
CrossRef175
Richard C. Boucher. (1996) Current status of CF gene therapy. Trends in Genetics 12:3, 81-84
CrossRef176
Robert C. Stern. (1996) Denmark to the rescue. Pediatric Pulmonology 21:3, 151-152
CrossRef177
(1996) Gene Therapy. New England Journal of Medicine 334:5, 332-333
Full Text178
Theodore Friedmann. (1996) Human gene therapy — an immature genie, but certainly out of the bottle. Nature Medicine 2:2, 144-147
CrossRef179
CHARLES COUTELLE, ROBERT WILLIAMSON. (1996) Liposomes and Viruses for Gene Therapy of Cystic Fibrosis. Journal of Aerosol Medicine 9:1, 79-88
CrossRef180
Larry G. Johnson, Raymond J. Pickles, Susan E. Boyles, Julia C. Morris, Hong Ye, Zhaoqing Zhou, John C. Olsen, Richard C. Boucher. (1996) In Vitro Assessment of Variables Affecting the Efficiency and Efficacy of Adenovirus-Mediated Gene Transfer to Cystic Fibrosis Airway Epithelia. Human Gene Therapy 7:1, 51-59
CrossRef181
Walter H. Günzburg, Brian Salmons. (1995) Virus vector design in gene therapy. Molecular Medicine Today 1:9, 410-417
CrossRef182
R. Sanders Williams. (1995) Human gene therapy — of tortises and hares. Nature Medicine 1:11, 1137-1138
CrossRef183
Leiden, Jeffrey M., . (1995) Gene Therapy — Promise, Pitfalls, and Prognosis. New England Journal of Medicine 333:13, 871-873
Full Text
- Letters
